With the Dems. coming into power there will be increasing pressure on the primary drug companies to cut prices... Pfizer, Merk, Astra, SGP, Roche, BMY, etc... will all be on the lookout for a company that can sell at lower costs. Mylan's generic lines and its pipeline will certainly garner interest.
Mylan is not and will never be a take over target. Big Time Poison Pill!
Remember, how Carl Icahn tried and failed to control this company? I wouldn't buy this stock and look at as a take over possibility. So, don't get your hopes up. This Management Team doesn't care about quick buck artists or Wall Street analysts. If you should wish for anything. Wish that Coury gets the boot. Any bad news is brutal. Good news is a reason to sell.
However, $1.38/share will be recognized and rewarded. That's why I'm in.
I don't think Icahn ever had any intention of buying Mylan, he was just exercising the well-refined art of greenmail. He's a master at it and there's no reason to think he ever wanted to get involved in the generic business. He just saw a juicy target and took advantage, and made a boatload of cash.